RxDoctor Payments Data

Adam Cohen, MD

Cardiovascular Disease · Horsham, PANPI 1942296140

Payments from drug & device makers

$185,019in general payments, 2019–2025

Across 557 payments — averaging $332.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$161K
  • Sanofi-aventis U.S. LLC$19K
  • Johnson & Johnson$1K
  • Regeneron Healthcare Solutions, Inc.$970
  • Pfizer$509
  • E.r. Squibb & Sons, L.L.C.$455
  • plus $2K from 19 others

What the payments were for

  • Speaking & faculty fees$163,60588%
  • Travel & lodging$10,0245%
  • Food & beverage$11,3826%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$185,019 in reported general payments places this provider in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$402,924
Medicare patients
921
Services billed
4,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban257$266,934
XareltoRivaroxaban114$147,838
Repatha SureclickEvolocumab162$122,412
EntrestoSacubitril/Valsartan47$53,605
Praluent PenAlirocumab53$29,169
Metoprolol Succinate404$7,180
Rosuvastatin Calcium370$5,263
Atorvastatin Calcium420$4,663
Icosapent Ethyl15$3,730
Ezetimibe103$2,496
Losartan Potassium232$2,467
Nitroglycerin40$2,262
Nadolol44$2,251
Valsartan54$2,203
Amiodarone Hcl71$2,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$509$266,934257 claims
Johnson & JohnsonXarelto$1,198$147,838114 claims
NovartisEntresto$346$53,60547 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Horsham

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →